Periods | Baseline | L-NMMA |
---|---|---|
PWV(m/s) | ||
Placebo | 5.3 ± 0.7 | 5.5 ± 0.5 |
Tolvaptan | 5.3 ± 0.6 | 5.6 ± 0.7* |
p (paired t-test, between) | 0.652 | 0.929 |
AI | ||
Placebo | 0.0 ± 18.7 | 3.7 ± 18.7 |
Tolvaptan | 1.2 ± 18.3 | 7.2 ± 17.5* |
p (paired t-test, between) | 0.646 | 0.064 |
CSBP | ||
Placebo | 100 ± 7 | 105 ± 4 |
Tolvaptan | 100 ± 4 | 107 ± 7* |
p (paired t-test, between) | 0.871 | 0.351 |
CDBP | ||
Placebo | 66 ± 12 | 70 ± 8* |
Tolvaptan | 64 ± 5 | 68 ± 8* |
p (Wilcoxon signed rank test, between) | 0.440 | 0.622 |